Spots Global Cancer Trial Database for egf816
Every month we try and update this database with for egf816 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer | NCT03292133 | Lung Cancer | EGF816 Gefitinib | 18 Years - | Massachusetts General Hospital | |
| A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer | NCT03292133 | Lung Cancer | EGF816 Gefitinib | 18 Years - | Massachusetts General Hospital | |
| Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations | NCT03529084 | Carcinoma, Non-... | EFG816 erlotinib or ge... | 18 Years - | Novartis | |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | NCT03333343 | EGFR-mutant Non... | EGF816 trametinib ribociclib LXH254 INC280 gefitinib | 18 Years - | Novartis | |
| Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | NCT02335944 | Non Small Cell ... | Capmatinib Nazartinib | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | NCT02323126 | Non Small Cell ... | EGF816 INC280 Nivolumab | 18 Years - | Novartis | |
| A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | NCT02108964 | Advanced Non-sm... | EGF816 | 18 Years - | Novartis | |
| Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | NCT02335944 | Non Small Cell ... | Capmatinib Nazartinib | 18 Years - | Novartis | |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | NCT03333343 | EGFR-mutant Non... | EGF816 trametinib ribociclib LXH254 INC280 gefitinib | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | NCT02323126 | Non Small Cell ... | EGF816 INC280 Nivolumab | 18 Years - | Novartis | |
| Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone | NCT03040973 | Advanced Solid ... | Capmatinib Nazartinib Gefitinib Osimertinib | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | NCT02323126 | Non Small Cell ... | EGF816 INC280 Nivolumab | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
